Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan making its case for becoming a standard of care for the glomerular disease.
The Diuretic Comparison Project trial, showing no difference in clinical events between diuretics chlorthalidone and hydrochlorothiazide for hypertension, is now published in NEJM.
The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.
Switching from regular salt to a low-sodium salt substitute has major public health benefits, including a reduction in stroke, cardiovascular events, and death, the new landmark SSaSS shows.